PMID: 6967639Jun 1, 1980Paper

Creation and properties of histocompatibility antigen-cell conjugates. II. Antibody tolerance after treatment with donor histocompatibility antigen chemically coupled to recipient spleen cells

Transplantation
R R Bollinger, D W Scott

Abstract

Histocompatibility (HC) antigens from Lewis (RT-11) and ACI (RT-1a) rats were solubilized and their tolerogenic potential alone or when conjugated to cellular carriers was investigated. The tolerogenic carrier potential of whole cells, crude membranes, and deoxycholate (DOC)-solubilized membranes was first determined by conjugating trinitrophenyl (TNP) groups to them and measuring their ability to prevent an anti-TNP plaque-forming cell response in rats after immunogenic challenge. Since whole lymphoid cells proved to be most effective in this system, DOC-solubilized allogeneic histocompatibility antigens were coupled to syngeneic lymphocytes, using carbodiimide cross-linking. Animals pretreated with this conjugate produced no alloantibody upon challenge with allogeneic cells. These results suggest that tolerance to allogeneic histocompatibility antigen can be produced by association of alloantigens on a tolerogenic self-carrier.

Citations

May 1, 1992·Journal of Neuroimmunology·K R McIntosh, D B Drachman
Jan 1, 1982·Annals of the New York Academy of Sciences·D W ScottL A Wilson
Jan 1, 1980·Immunological Reviews·D W ScottJ T Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.